vs
Side-by-side financial comparison of Cue Biopharma, Inc. (CUE) and HARTE HANKS INC (HHS). Click either name above to swap in a different company.
HARTE HANKS INC is the larger business by last-quarter revenue ($39.9M vs $21.9M, roughly 1.8× Cue Biopharma, Inc.). Cue Biopharma, Inc. runs the higher net margin — 7.2% vs 5.5%, a 1.7% gap on every dollar of revenue. On growth, Cue Biopharma, Inc. posted the faster year-over-year revenue change (1292.3% vs -15.4%). Over the past eight quarters, Cue Biopharma, Inc.'s revenue compounded faster (257.5% CAGR vs -6.4%).
Cue Biopharma is a clinical-stage biotechnology company focused on developing novel targeted immunotherapies for cancer, autoimmune disorders, and inflammatory diseases. Its proprietary platform enables precise T-cell activity modulation, with core operations in North America and global pharma partnerships to advance lead product candidates through clinical trials.
Harte Hanks is a global marketing services company headquartered in Boston, Massachusetts. Harte Hanks services include analytics, strategy, marketing technology, creative services, digital marketing, customer care, direct mail, logistics, and fulfillment.
CUE vs HHS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $21.9M | $39.9M |
| Net Profit | $1.6M | $2.2M |
| Gross Margin | — | — |
| Operating Margin | 9.0% | -0.3% |
| Net Margin | 7.2% | 5.5% |
| Revenue YoY | 1292.3% | -15.4% |
| Net Profit YoY | 116.7% | — |
| EPS (diluted) | $0.05 | $0.30 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $21.9M | $39.9M | ||
| Q3 25 | $2.1M | $39.5M | ||
| Q2 25 | $3.0M | $38.6M | ||
| Q1 25 | $421.0K | $41.6M | ||
| Q4 24 | $1.6M | $47.1M | ||
| Q3 24 | $3.3M | $47.6M | ||
| Q2 24 | $2.7M | $45.0M | ||
| Q1 24 | $1.7M | $45.4M |
| Q4 25 | $1.6M | $2.2M | ||
| Q3 25 | $-7.4M | $-2.3M | ||
| Q2 25 | $-8.5M | $-335.0K | ||
| Q1 25 | $-12.3M | $-392.0K | ||
| Q4 24 | — | — | ||
| Q3 24 | $-8.7M | $142.0K | ||
| Q2 24 | $-10.2M | $-27.8M | ||
| Q1 24 | $-12.3M | $-171.0K |
| Q4 25 | 9.0% | -0.3% | ||
| Q3 25 | -353.4% | 1.3% | ||
| Q2 25 | -292.3% | 0.1% | ||
| Q1 25 | -2921.4% | -0.1% | ||
| Q4 24 | — | -3.3% | ||
| Q3 24 | -264.2% | 4.0% | ||
| Q2 24 | -390.6% | 3.0% | ||
| Q1 24 | -737.8% | 0.8% |
| Q4 25 | 7.2% | 5.5% | ||
| Q3 25 | -346.6% | -5.8% | ||
| Q2 25 | -287.1% | -0.9% | ||
| Q1 25 | -2911.4% | -0.9% | ||
| Q4 24 | — | — | ||
| Q3 24 | -259.6% | 0.3% | ||
| Q2 24 | -382.7% | -61.8% | ||
| Q1 24 | -719.1% | -0.4% |
| Q4 25 | $0.05 | $0.30 | ||
| Q3 25 | $-0.07 | $-0.31 | ||
| Q2 25 | $-0.09 | $-0.05 | ||
| Q1 25 | $-0.17 | $-0.05 | ||
| Q4 24 | — | $-0.31 | ||
| Q3 24 | $-0.17 | $0.02 | ||
| Q2 24 | $-0.20 | $-3.84 | ||
| Q1 24 | $-0.25 | $-0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.1M | $5.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $26.4M | $20.5M |
| Total Assets | $42.2M | $91.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.1M | $5.6M | ||
| Q3 25 | $11.7M | $6.5M | ||
| Q2 25 | $27.5M | $4.8M | ||
| Q1 25 | $13.1M | $9.0M | ||
| Q4 24 | $22.5M | $9.8M | ||
| Q3 24 | $32.4M | $5.9M | ||
| Q2 24 | $30.0M | $11.0M | ||
| Q1 24 | $41.0M | $11.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $1.0M | — | ||
| Q2 24 | $2.0M | — | ||
| Q1 24 | $3.0M | — |
| Q4 25 | $26.4M | $20.5M | ||
| Q3 25 | $13.2M | $19.9M | ||
| Q2 25 | $18.2M | $22.2M | ||
| Q1 25 | $6.6M | $21.4M | ||
| Q4 24 | $17.5M | $21.7M | ||
| Q3 24 | $25.4M | $21.0M | ||
| Q2 24 | $21.6M | $20.6M | ||
| Q1 24 | $30.0M | $20.0M |
| Q4 25 | $42.2M | $91.8M | ||
| Q3 25 | $31.6M | $92.7M | ||
| Q2 25 | $40.7M | $95.0M | ||
| Q1 25 | $22.3M | $100.6M | ||
| Q4 24 | $32.2M | $101.8M | ||
| Q3 24 | $44.8M | $108.1M | ||
| Q2 24 | $42.3M | $109.7M | ||
| Q1 24 | $54.0M | $113.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.04× | — | ||
| Q2 24 | 0.09× | — | ||
| Q1 24 | 0.10× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.1M | $737.0K |
| Free Cash FlowOCF − Capex | — | $-686.0K |
| FCF MarginFCF / Revenue | — | -1.7% |
| Capex IntensityCapex / Revenue | 0.0% | 3.6% |
| Cash ConversionOCF / Net Profit | -0.68× | 0.33× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-4.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.1M | $737.0K | ||
| Q3 25 | $-9.0M | $3.2M | ||
| Q2 25 | $-3.4M | $-4.8M | ||
| Q1 25 | $-8.2M | $-818.0K | ||
| Q4 24 | $-36.3M | $4.0M | ||
| Q3 24 | $-7.5M | $-2.9M | ||
| Q2 24 | $-10.0M | $1.6M | ||
| Q1 24 | $-9.8M | $-5.7M |
| Q4 25 | — | $-686.0K | ||
| Q3 25 | — | $2.2M | ||
| Q2 25 | $-3.4M | $-5.1M | ||
| Q1 25 | $-8.3M | $-923.0K | ||
| Q4 24 | $-36.4M | $3.4M | ||
| Q3 24 | $-7.5M | $-4.9M | ||
| Q2 24 | $-10.0M | $926.0K | ||
| Q1 24 | $-9.8M | $-6.2M |
| Q4 25 | — | -1.7% | ||
| Q3 25 | — | 5.5% | ||
| Q2 25 | -116.5% | -13.1% | ||
| Q1 25 | -1976.7% | -2.2% | ||
| Q4 24 | -2309.3% | 7.3% | ||
| Q3 24 | -225.7% | -10.2% | ||
| Q2 24 | -376.2% | 2.1% | ||
| Q1 24 | -573.0% | -13.7% |
| Q4 25 | 0.0% | 3.6% | ||
| Q3 25 | 0.0% | 2.5% | ||
| Q2 25 | 0.9% | 0.6% | ||
| Q1 25 | 35.6% | 0.3% | ||
| Q4 24 | 4.2% | 1.3% | ||
| Q3 24 | 0.0% | 4.0% | ||
| Q2 24 | 0.4% | 1.5% | ||
| Q1 24 | 3.2% | 1.2% |
| Q4 25 | -0.68× | 0.33× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -20.76× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CUE
| Immuno Scape Collaboration And License Agreement | $9.5M | 43% |
| BI Collaboration And License Agreement | $8.1M | 37% |
| Other | $4.3M | 20% |
HHS
| Fulfillment And Logistics Services | $17.3M | 43% |
| Customer Care | $13.7M | 34% |
| Other | $8.9M | 22% |
